Adapalene Companies, Latest Updates and Market Growth 2026-2035

Top Adapalene Market Companies, Growth and Latest Updates 2026

Now it’s effortless to manage all your Market data with 30+ powerful features for your business in one powerful place: Access the Dashboard

Supply Chain Analysis

R&D:

• Research and development (R&D) for adapalene involves advanced formulation technology, characterization, stability testing, and in vitro/in vivo effectiveness research.
• Key Players: Sun Pharmaceutical Industries Ltd. and Dr. Reddy’s Laboratories Ltd.

Manufacturing Processes:

• Manufacturing processes in adapalene involve the biochemical synthesis of the active pharmaceutical ingredient (API) and the pharmaceutical formulation into topical products such as gels or creams.
• Key Players: Perrigo Company plc and Glenmark Pharmaceuticals Ltd.

Patient Services:

• Patient services, including adapalene, primarily focus on the diagnosis, prescription, and long-term management of acne vulgaris and different dermatological conditions.
• Key Players: Galderma S.A. and Teva Pharmaceutical Industries Ltd

Market Growth

The global adapalene market size was estimated at USD 611.1 million in 2025 and is predicted to increase from USD 635.18 million in 2026 to approximately USD 899.37 million by 2035, expanding at a CAGR of 3.94% from 2026 to 2035.

Our experts provide regional insights, growth stats, competitor analysis and many more customized requirements to help you stay ahead: Download for FREE

Recent Developments in the Adapalene Market

• In August 2025, Bausch Health, Canada Inc., part of Bausch Health Companies Inc., a worldwide, diversified pharmaceutical organization, announced that PrCABTREO gel 1.2% w/w, 0.15% w/w, and 3.1% w/w, for the treatment of acne vulgaris,1 is now available to recipients of the public drug plans of Quebec and Saskatchewan
• In September 2025,  Sol-Gel Technologies, Ltd., a dermatology organization, pioneering treatments for patients with severe skin conditions, conducting a Phase-3 clinical trial of SGT-610 for Gorlin syndrome, a Phase-1b, double-blinded clinical trial of SGT-210 on Darier disease patients, and with two approved large-category dermatology products, TWYNEO and EPSOLAY, announced that Health Canada issued a Notice of Compliance (NOC) for EPSOLAY for the treatment of inflammatory lesions of rosacea in adults.
• In April 2025, Sol-Gel Technologies, Ltd., a clinical-stage dermatology organization, announced it had entered into a product purchase agreement with a subsidiary of Mayne Pharma Group Limited for the sale and exclusive license of the U.S. rights to EPSOLAY and TWYNEO.